Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Oct 11.

Published in final edited form as: J Hypertens. 2016 May;34(5):1005–1010. doi: 10.1097/HJH.0000000000000870

TABLE 2.

Characteristics and the results of bivariate analysis for favorable SBP reduction (≥10mmHg) of patients treated with spironolactone

Characteristics	Favorable SBP Reduction
Characteristics	All (n = 79)	Yes (n = 54)	No (n = 25)	P value
Diabetes mellitus, n (%)	26 (32.9%)	19 (73.1%)	7 (28%)	0.53
Obstructive sleep apnea, n (%)	24 (30.4%)	16 (29.6%)	8 (32%)	0.83
Coronary artery disease, n (%)	4 (5.1%)	3 (5.6%)	1 (4%)	1.00
Heart failure, n (%)	8 (10.1%)	5 (9.3%)	3 (12%)	0.7
Dyslipidemia, n (%)	36 (45.6%)	31 (57.4%)	12 (48%)	0.43
Atrial fibrillation, n (%)	5 (6.3%)	3 (5.6%)	2 (8%)	0.65
Stroke, n (%)	2 (2.5%)	1 (1.9%)	1 (4%)	0.54
Primary aldosteronism	36 (46.2%)	30 (56.6%)	6 (24%)	0.007

Primary aldosteronism: plasma renin activity less than 1ng/ml/h and urinary aldosterone more than 12ug/24 h.